<DOC>
	<DOCNO>NCT00345683</DOCNO>
	<brief_summary>The booster phase study evaluate safety Hib-MenCY-TT vaccine compare control group receive license Hib conjugate vaccine 12 15 month age . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00345579 ) . No new recruitment take place booster phase study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Safety Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine , Given 12 15 Months Age .</brief_title>
	<detailed_description>Hib-MenCY-TT = GSK Biologicals ' Haemophilus influenzae type b Neisseria meningitidis serogroups C Y-tetanus toxoid conjugate vaccine . The study conduct single blind manner 30 day administration booster dose ; extend safety follow-up booster dose conduct unblinded manner . All subject receive Prevnar , M-M-R II Varivax study vaccine , preferencially co-administered booster dose Hib-MenCY-TT/PedvaxHIB . Note : This protocol post deal objective &amp; outcome measure booster phase study . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT00345579 )</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects enrol primary study ( NCT00345579 ) eligible participate booster study Subjects administer MMR II Varivax criterion apply : History measles , mumps , rubella varicella . Previous vaccination measles , mumps , rubella varicella . Hypersensitivity component vaccine , include gelatin neomycin . Patients receive immunosuppressive therapy . Individuals blood dyscrasia , leukemia , lymphomas type , malignant neoplasm affect bone marrow lymphatic system . Individuals primary acquire immunodeficiency state . Individuals family history congenital hereditary immunodeficiency , immune competence potential vaccine recipient demonstrate . Individuals active tuberculosis . Acute disease time booster vaccination</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>H. influenzae type B vaccine</keyword>
	<keyword>Infants</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Vaccines , conjugate</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Comparative study</keyword>
	<keyword>Safety</keyword>
	<keyword>Humans</keyword>
</DOC>